Immune to Cancer: The CRI Blog
-
Bikes, Beers, and One Cause to Cure All Cancers
On June 26, 2018, 48 cyclists—CRI Associate Board members, family, and friends—biked together at SWERVE Fitness Flatiron…
-
Team Cycling for the Answer to Cancer
On June 21, 2018, 60 employees from the Mitsubishi UFJ Financial Group participated in a team-based studio…
-
30 Days of CRI Impact: Getting to Know Your Cancer-Fighting Immune Cells
This week’s CRI-funded breakthroughs highlight the anti-tumor capabilities of T cells, macrophages, and natural killer cells.
-
Taking #WearWhite Day to a Whole New Level
Several CRI staffers headed down to Maryland to participate in a celebratory #WearWhite Day employee engagement event hosted…
-
Lessons on Talking to Your Oncologist About Cancer Immunotherapy
A patient advocate and oncologist discuss the need for trust and communication throughout an immunotherapy clinical trial.
-
Hiking the Appalachian Trail for Cancer Research: A Q&A with Dan Harris
As a survivor of two bouts of cancer—testicular and lung—and having lost friends to the disease, Dan…
-
Our Supporters #WearWhite for a Future Immune to Cancer
On June 15, hundreds of scientists, patients, advocates, and healthcare professionals donned white apparel for our sixth…
-
30 Days of CRI Impact: Understanding Immune Checkpoints and Pathways
This week’s CRI breakthroughs deal with the development of checkpoint immunotherapy and other advances that have helped…
-
First Checkpoint Immunotherapy Approved for Advanced Cervical Cancer
Pembrolizumab, a PD-1-targeting immunotherapy, was approved for recurrent advanced cervical cancer that expresses PD-L1.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.